Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
Titel:
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
Auteur:
Dreyling, M. Morschhauser, F. Bouabdallah, K. Bron, D. Cunningham, D. Assouline, S.E. Verhoef, G. Linton, K. Thieblemont, C. Vitolo, U. Hiemeyer, F. Giurescu, M. Garcia-Vargas, J. Gorbatchevsky, I. Liu, L. Koechert, K. Peña, C. Neves, M. Childs, B.H. Zinzani, P.L.